Trial Profile
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Evacetrapib (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
- Indications Hypercholesterolaemia; Low HDL cholesterol
- Focus Pharmacogenomic; Therapeutic Use
- 17 Nov 2015 Results published in the Journal of the American College of Cardiology
- 16 Nov 2011 Results published in JAMA: the Journal of the American Medical Association.
- 13 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.